A single-dose, 3-way, 3-period, 6-sequence, crossover study to evaluate the bioequivalence of Emtricitabine/Rilpivirine/Tenofovir-alafenamide as a single tablet regimen versus Cobicistat/Elvitegravir/Emtricitabine/Tenofovir-alafenamide and Rilpivirine in healthy volunteers
Latest Information Update: 04 Mar 2016
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Rilpivirine
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 04 Mar 2016 New trial record